NCT05592457

Brief Summary

Urinary stones are a common disease affecting one in 11 people . Their clinical presentation varies from being silent to severe loin pain owing to urinary obstruction. Currently, ESWL is the treatment of choice for most renal calculi ⩽30 mm, with success rates of 60-99%. Although many treatment options exist, ESWL has the advantages of simplicity and non-invasiveness. In contrast, failure of a first ESWL attempt requires a follow-up ESWL procedure, or an alternative procedure, both of which increase medical costs. Advancements in imaging have significantly contributed to this process. In the mid- 1990s, computed tomography (CT) began to replace intravenous urography (IVU), abdominal films (KUB), and ultrasound (US) in stone diagnosis. Studies demonstrated that CT had superior sensitivity and specificity for stone diagnosis compared to the aforementioned modalities. Now non-contrast multidetector CT (NC-MDCT) is the gold standard for the detection of urinary system calculi. CT is also clinically useful as it can show alternate renal and non-renal pathology if present. Many factors have been reported to predict ESWL outcome, such as skin-to-stone distance (SSD), stone size, stone location, multiplicity, the energy used, and Hounsfield Unit (HU) values measured by non-contrast computed tomography (NCCT).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
55

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2022

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

October 20, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 24, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2024

Completed
Last Updated

October 25, 2022

Status Verified

October 1, 2022

Enrollment Period

1 year

First QC Date

October 20, 2022

Last Update Submit

October 22, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • ct follow up during swl

    Correlation between the stone density before and during ESWL sessions to determine if this predicts the success prevent new ESWL.

    3 weeks

  • stone Hounsfield

    Determine the role of the density of the residual stone fragments in the prediction of the complication during ESWL.

    3weeks

Secondary Outcomes (1)

  • density of stone and other factors

    3weeks

Interventions

MSCTDIAGNOSTIC_TEST

multislice computed tomography

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

* Firstly All studies were performed by using a CT device. * the mean Hounsfield unit was calculated. The skin-to-stone distance (SSD) was calculated by measuring three distances from the stone to the skin at 0, 45, and 90°; * after the first session of ESWL by one to three weeks Low dose NCCT(MA=175)will be done to determine the measurements of the fragments or the stone if not fragmented including their density and size will be taken, For the density, if decreased or not changed continuation versus stop will be evaluated, while for the size the fragmentation will be assessed as 1- complete fragmentation is the fragment size \<4 mm, 2- partial fragmentation if size = 4-5 mm and 3- incomplete fragmentation if the size of fragment more than or equal 6 mm.

You may qualify if:

  • patients older than 18 years.
  • stone size up to 25 mm for renal pelvic stones and up to 15 mm for upper ureteric stones.
  • SSD \< 11 cm.

You may not qualify if:

  • any patient with contraindications to ESWL as
  • uncontrolled urinary infection.
  • clotting alterations.
  • aortic or renal artery aneurysm.
  • pregnancy.
  • serious skeletal malformations.
  • serious obesity and or contraindications to CT as pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University Hospital

Asyut, 11751, Egypt

RECRUITING

Related Publications (4)

  • Wolf JS Jr, Clayman RV. Percutaneous nephrostolithotomy. What is its role in 1997? Urol Clin North Am. 1997 Feb;24(1):43-58. doi: 10.1016/s0094-0143(05)70353-0.

    PMID: 9048851BACKGROUND
  • Rassweiler JJ, Renner C, Chaussy C, Thuroff S. Treatment of renal stones by extracorporeal shockwave lithotripsy: an update. Eur Urol. 2001 Feb;39(2):187-99. doi: 10.1159/000052435.

    PMID: 11223679BACKGROUND
  • Johnson EK, Faerber GJ, Roberts WW, Wolf JS Jr, Park JM, Bloom DA, Wan J. Are stone protocol computed tomography scans mandatory for children with suspected urinary calculi? Urology. 2011 Sep;78(3):662-6. doi: 10.1016/j.urology.2011.02.062. Epub 2011 Jun 30.

    PMID: 21722946BACKGROUND
  • Weld KJ, Montiglio C, Morris MS, Bush AC, Cespedes RD. Shock wave lithotripsy success for renal stones based on patient and stone computed tomography characteristics. Urology. 2007 Dec;70(6):1043-6; discussion 1046-7. doi: 10.1016/j.urology.2007.07.074.

    PMID: 18158009BACKGROUND

MeSH Terms

Conditions

Urinary Calculi

Condition Hierarchy (Ancestors)

UrolithiasisUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesCalculiPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • gehan sayed, MD

    Assiut University

    STUDY DIRECTOR
  • Doria mohamed, md

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Dina Essam, resident

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principle investigator

Study Record Dates

First Submitted

October 20, 2022

First Posted

October 24, 2022

Study Start

October 15, 2022

Primary Completion

October 30, 2023

Study Completion

October 30, 2024

Last Updated

October 25, 2022

Record last verified: 2022-10

Locations